Eli Lilly & Co. (LLY)$1065.00
Market Cap: 737.66 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Eli Lilly & Co. (LLY).
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
DCF ready
Valuation
43.4x
EV/FCF, 2.3% FCF yield
Quality
77.8%
ROIC, 25.8% FCF margin
Growth
21.6%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 1.6x current ratio
Superinvestors
7
Top: Polen Capital Management (5.8%)
Strengths to research
- Revenue compounded at 21.6% over five years.
- Free cash flow compounded at 20.9% over five years.
- Return on equity is strong at 77.8%.
- Free cash flow margin is healthy at 25.8%.
Watchouts
- P/E is elevated at 46.4x.
- P/FCF is elevated at 43.9x.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for LLY.
Grade C
58
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| LLY Target | Eli Lilly & Co. | $737.7B | 46.4x | 43.4x | 77.8% | 21.6% | 25.8% | N/A | N/A | N/A |
| JNJ | Johnson & Johnson | $372.9B | 21.2x | 20.0x | 21.8% | 2.7% | 20.9% | 67.9% | N/A | N/A |
| ABBV | AbbVie Inc. | $346.8B | 91.4x | 22.8x | 6.9% | 6.0% | 29.1% | N/A | 3.7x | N/A |
| NVO | Novo Nordisk A S | $305.8B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| RHHBY | Roche Holding AG ADR | $265.2B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| RHHVF | Roche Holdings AG DIV RT | $263.8B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| NVS | Novartis AG | $223.3B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| MRK | Merck & Co. | $208.5B | 16.8x | 15.7x | 34.7% | 9.4% | 19.0% | N/A | N/A | N/A |
| AMGN | Amgen | $150.6B | 23.8x | 24.2x | 12.2% | 7.6% | 22.0% | N/A | 3.2x | N/A |
Financial Charts
No financial data available for LLY (annual).
7 superinvestors own LLY
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Polen Capital Management Polen Capital Management | 914,557 | $841M | 5.82% | 0.0% |
| Mairs & Power Growth Fund Mairs & Power Growth Fund | 326,306 | $300M | 3.07% | 0.0% |
| Jensen Investment Management Jensen Investment Management | 230,671 | $212M | 4.18% | 0.0% |
| Dodge & Cox Dodge & Cox | 42,012 | $39M | 0.02% | 0.0% |
| Bill Nygren Oakmark Select Fund | 450 | $414,000 | 0.00% | 0.0% |
| Torray Funds Torray Funds | 398 | $366,000 | 0.06% | 0.0% |
| David Katz Matrix Asset Advisors | 311 | $286,000 | 0.03% | 0.0% |